• AGM 2020 - Kazia stands poised to commence a pivotal study for the registration of paxalisib in glioblastoma read more

Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.